RE: RNS7 Jul 2023 10:25
Reading thru 4th July RNS - extract below, could it be these large Pharma’s with whom they were also inferring to possible licensing deals??
Looking ahead, the pipeline for fee-for-service revenues for the year to June 2024 ("FY24") currently stands at approximately GBP2.2 million across 30 discrete fee-for-service projects (after risk-adjustment for anticipated commercial and scientific attrition). Note that this figure only includes opportunities for which the Group has current visibility and further opportunities over the course of FY24 are expected to increase this figure. In addition, this figure does not include licensing opportunities which could make a meaningful upside contribution to revenue .